TB-500 vs GHK-Cu
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
TB-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. Most TB-500 products reproduce the short LKKTETQ sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. Here is the honest part: there are essentially no completed human trials of the TB-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing.
Also: Copper Peptide, Glycyl-L-histidyl-L-lysine copper
GHK-Cu is the copper(II) complex of GHK, a naturally occurring human tripeptide (glycyl-L-histidyl-L-lysine) found in blood plasma, saliva and urine, whose levels decline with age. It is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. It is not an FDA-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies.
Key Comparison Insights
- TB-500 is categorized as Healing, while GHK-Cu is Skin & Hair.
- GHK-Cu has stronger research evidence (Human Trials) compared to TB-500 (Animal Studies).
- These peptides are often used together in healing protocols for synergistic effects.
Detailed Comparison
| Attribute | TB-500 | GHK-Cu |
|---|---|---|
| Category | Healing | Skin & Hair |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Thymosin beta-4 works by grabbing onto G-actin, the building-block form of actin, and acting as the main reservoir cells use to remodel their cytoskeleton. That control over actin lets cells migrate into wounds, which is the proposed basis for faster tissue repair. The active heptapeptide sequence LKKTETQ is the piece that does the actin binding, and TB-500 is built around it. Beyond cell movement, thymosin beta-4 has shown anti-inflammatory effects and pro-angiogenic activity in lab models. Keep in mind that injecting a short synthetic fragment is not guaranteed to reproduce everything the full protein does, so the mechanism story is borrowed largely from research on the parent molecule. | GHK has a strong affinity for copper(II) ions and forms the GHK-Cu complex, which is thought to deliver copper to cells for copper-dependent processes such as connective-tissue formation and antioxidant defense. Its most striking documented activity is broad gene-expression modulation: in cultured human cells, GHK shifts the expression of a large fraction of genes, tending to upregulate tissue-repair genes and downregulate some inflammatory pathways. It stimulates fibroblasts to produce collagen and other extracellular-matrix proteins, supports keratinocyte and blood-vessel activity, and shows antioxidant and anti-inflammatory effects in lab models. Importantly, the copper-binding hypothesis does not fully explain these gene effects, and researchers note the precise mechanism is not yet fully understood. |
| Common Dosing | 2-2.5 mg twice weekly (loading), then 2.5 mg once weekly (maintenance) 2x weekly for 4-6 weeks, then 1x weekly | 1-2 mg daily (injection) or 0.05% topical Once daily |
| Administration | Subcutaneous or intramuscular injection | Subcutaneous injection or topical application |
| Typical Duration | 4-6 weeks loading, then maintenance | Varies by application |
| Best Time to Take | Morning or evening | Evening (for skin/recovery) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The strongest evidence is preclinical and is mostly about full-length thymosin beta-4, not the TB-500 fragment. Animal studies consistently show accelerated wound healing, reduced scarring, and improved recovery in tendon, skin, and cardiac injury models. On the human side, the biotech company RegeneRx ran the molecule (as RGN-259 eye drops and RGN-352 injection) through actual clinical trials: a placebo-controlled Phase 3 study of RGN-259 in neurotrophic keratopathy reported corneal healing in 6 of 10 treated patients versus 1 of 8 on placebo, and an injectable cardiac program reached Phase 2 before a manufacturing hold. But those programs used full-length thymosin beta-4, not the 7-amino-acid TB-500 fragment sold for research. For the fragment specifically, there are no completed, published human efficacy trials for muscle or tendon repair, and a recently listed cardiovascular biomarker study is early-stage. So: real animal data, real human data for the parent protein, and a near-total gap for TB-500 as sold. | Much of the mechanistic and efficacy evidence is from cell culture and animal studies. In animals, GHK and GHK-containing dressings improved wound contraction, granulation tissue and collagen deposition in rabbit and rat wounds, and showed protective effects in lung-injury models. In cells, GHK increases collagen, elastin and growth-factor production by fibroblasts and protects keratinocytes from UV damage. Human evidence exists but is limited to small cosmetic trials: facial-cream and eye-cream studies in modest numbers of women (for example a 71-subject facial study and a 41-subject eye-cream study) reported improvements in skin density, thickness and wrinkle appearance. These trials are small and focused on topical skin endpoints, so they do not establish injected or systemic benefits, and there are no large independent randomized trials. Honest summary: strong lab and animal data plus encouraging small topical human studies, but evidence for injected use is preliminary. |
Frequently Asked Questions: TB-500 vs GHK-Cu
What is the difference between TB-500 and GHK-Cu?
TB-500 is a healing peptide that tb-500 is a synthetic peptide that copies the active region of thymosin beta-4, a natural protein that controls how cells build and move their internal skeleton. most tb-500 products reproduce the short lkktetq sequence (residues 17 to 23) responsible for binding actin and driving cell migration, which is why it gets marketed for tendon, muscle, and wound repair. here is the honest part: there are essentially no completed human trials of the tb-500 fragment itself, and almost all the human clinical data is for the full-length thymosin beta-4 molecule, which is related but not the same thing. GHK-Cu is a skin & hair peptide that ghk-cu is the copper(ii) complex of ghk, a naturally occurring human tripeptide (glycyl-l-histidyl-l-lysine) found in blood plasma, saliva and urine, whose levels decline with age. it is researched and widely used in cosmetic skincare for skin regeneration, wound healing, collagen support and anti-aging. it is not an fda-approved drug; it appears in over-the-counter cosmetics and as a research or compounded peptide, with most human evidence coming from small topical-skincare studies. The main differences lie in their mechanisms of action and clinical applications.
Which is better, TB-500 or GHK-Cu?
Neither is universally "better" - the choice depends on your specific goals. TB-500 is typically used for healing purposes, while GHK-Cu is used for skin & hair. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can TB-500 and GHK-Cu be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using TB-500 and GHK-Cu together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.